Eluminex Biosciences Limited

Founded in 2020 and based in Suzhou, China, Eluminex Biosciences Limited operates as a biotechnology company that researches and develops novel therapies for major eye diseases. It also established a branch office in San Francisco in 2021. The founder of the company, Jinzhong Zhang, was the pre-clinical vice president of Graybug Vision. Charles Semba, the Chief Medical Officer, worked at SARcode Bioscience, ForSight VISION5, and Gragybug Vision.

In July 2021, Eluminex Biosciences acquired exclusive rights to the biosynthetic corneal technology and recombinant human type III collagen platform from Enabase, Inc. In August 2023, Eluminex Biosciences Limited raised USD 10 million in series B+ funding from new investor Suzhou Industry Investment Group and returning investor Oriza Holdings. Eluminex Biosciences Limited has developed a full-length type III human collagen with a three-stranded helix structure through synthetic biology technology. The biosynthetic corneas made from type III human collagen can treat visual defects associated with corneal blindness.

The company's biosynthetic corneas are registered for clinical trials as Class III medical devices. The pipelines offered by the company include EB-105, EB-110, EB-116, EB-301, and EB-401. In the ophthalmology field, it is developing multiple next-generation anti-VEGF multi-valent bio-macromolecules for the treatment of age- and diabetes-related retinal diseases and other retinal vascular diseases. In the field of ophthalmology, it is developing multiple next-generation anti-VEGF multi-target biomolecules for the treatment of age-related and diabetes-induced retinal diseases, with an initial program scheduled to enter the clinic in the United States in 2024.